Accelerated stability studies of abatacept formulations: comparison of freeze-thawing- and agitation-induced stresses.

Accelerated degradation studies are frequently used to screen for formulation conditions that confer adequate shelf life for therapeutic proteins. To speed development cycles, degradation is often accelerated by application of conditions that expose proteins to elevated temperatures, dynamic air-water interfaces created by agitation, or stresses induced by freeze-thaw cycling. The purpose of this case study was to compare freeze-thaw- and agitation-induced aggregations with aggregation previously studied at elevated temperatures (Fast J, Cordes AA, Carpenter JF, Randolph TW. 2009. Biochemistry 48:11724-11736) using the therapeutic fusion protein abatacept as a model. The stability of abatacept against aggregation induced by the freeze-thaw and agitation degradation methods was assessed by size-exclusion chromatography (SEC) and microflow imaging (MFI) analysis. pH conditions that were previously found to increase conformational stability of abatacept and reduce aggregation during incubation at elevated temperature (Fast J, Cordes AA, Carpenter JF, Randolph TW. 2009. Biochemistry 48:11724-11736) also reduced aggregation induced by freeze-thaw cycling and by agitation in this study. Especially in the case of the freeze-thaw cycling, wherein the formation of aggregates was not readily detectable by SEC, MFI proved to be a useful method to characterize the stability of the formulations against aggregation.

[1]  Amber Haynes Fradkin,et al.  Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins. , 2011, Journal of pharmaceutical sciences.

[2]  W. Jiskoot,et al.  Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  C. R. Thomas,et al.  Effects of shear on proteins in solution , 2011, Biotechnology Letters.

[4]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[5]  Theodore W Randolph,et al.  Physical instability of a therapeutic Fc fusion protein: domain contributions to conformational and colloidal stability. , 2009, Biochemistry.

[6]  J. Philo,et al.  A critical review of methods for size characterization of non-particulate protein aggregates. , 2009, Current pharmaceutical biotechnology.

[7]  L. Bell,et al.  Effect of surfactants on the physical stability of recombinant human growth hormone. , 1995, Journal of pharmaceutical sciences.

[8]  Nitin Rathore,et al.  Current Perspectives on Stability of Protein Drug Products during Formulation, Fill and Finish Operations , 2008, Biotechnology progress.

[9]  Marisa K Joubert,et al.  Classification and Characterization of Therapeutic Antibody Aggregates , 2011, The Journal of Biological Chemistry.

[10]  Michael J. Pikal,et al.  Protein Stability During Freezing: Separation of Stresses and Mechanisms of Protein Stabilization , 2007, Pharmaceutical development and technology.

[11]  Mark Durst,et al.  Scan-rate-dependent melting transitions of interleukin-1 receptor (type II): elucidation of meaningful thermodynamic and kinetic parameters of aggregation acquired from DSC simulations. , 2005, Journal of the American Chemical Society.

[12]  Erinc Sahin,et al.  Predicting solution aggregation rates for therapeutic proteins: approaches and challenges. , 2011, International journal of pharmaceutics.

[13]  Christopher J Roberts,et al.  Predicting accelerated aggregation rates for monoclonal antibody formulations, and challenges for low-temperature predictions. , 2011, Journal of pharmaceutical sciences.

[14]  Lubert Stryer,et al.  Protein structure and function , 2005, Experientia.

[15]  Steven Kozlowski,et al.  Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. , 2009, Journal of pharmaceutical sciences.

[16]  Vincent J. Sullivan,et al.  Evaluation of the effect of syringe surfaces on protein formulations. , 2011, Journal of pharmaceutical sciences.

[17]  A. Faude,et al.  Fast determination of conditions for maximum dynamic capacity in cation-exchange chromatography of human monoclonal antibodies. , 2007, Journal of chromatography. A.

[18]  C. Pace,et al.  Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding , 1995, Protein science : a publication of the Protein Society.

[19]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[20]  Jared S. Bee,et al.  Effects of surfaces and leachables on the stability of biopharmaceuticals. , 2011, Journal of pharmaceutical sciences.

[21]  Hanns-Christian Mahler,et al.  Shaken, not stirred: mechanical stress testing of an IgG1 antibody. , 2008, Journal of pharmaceutical sciences.

[22]  J. Carpenter,et al.  Engineering challenges of protein formulations , 2007 .

[23]  C. Pace.  Determination and analysis of urea and guanidine hydrochloride denaturation curves. , 1986, Methods in enzymology.

[24]  R. Lewis,et al.  The effects of surface adsorption on the thermal stability of proteins , 1992, Biotechnology and bioengineering.

[25]  Amber Haynes Fradkin,et al.  Immunogenicity of aggregates of recombinant human growth hormone in mouse models. , 2009, Journal of pharmaceutical sciences.

[26]  Eiji Sawa,et al.  Prevention of stirring-induced microparticle formation in monoclonal antibody solutions. , 2010, Biological & pharmaceutical bulletin.

[27]  E. Gabellieri,et al.  Proteins in frozen solutions: evidence of ice-induced partial unfolding. , 1996, Biophysical journal.

[28]  Joey Pollastrini,et al.  Response of a concentrated monoclonal antibody formulation to high shear , 2009, Biotechnology and bioengineering.

[29]  A. Rosenberg,et al.  Effects of protein aggregates: An immunologic perspective , 2006, The AAPS Journal.

[30]  Chung C. Hsu,et al.  Protein denaturation by combined effect of shear and air-liquid interface. , 1997, Biotechnology and bioengineering.

[31]  Theodore W Randolph,et al.  Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: insights into the roles of particles in the protein aggregation pathway. , 2011, Journal of pharmaceutical sciences.

[32]  S. Hagen,et al.  Do protein molecules unfold in a simple shear flow? , 2006, Biophysical journal.

[33]  J L Cleland,et al.  Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions. , 1998, Journal of pharmaceutical sciences.